Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Report from the 5th cardiovascular outcome trial (CVOT) summit
Oliver Schnell, Eberhard Standl, Xavier Cos, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis
Mahin Chowdhury, Sarah J Nevitt, Aikaterini Eleftheriadou, et al.
BMJ Open Diabetes Research & Care (2021) Vol. 9, Iss. 2, pp. e002480-e002480
Open Access | Times Cited: 65
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes
Mónica Gallego, Julián Zayas-Arrabal, Amaia Alquiza, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36
Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital
Yiling Zhou, Yonggang Zhang, Rui Zhang, et al.
Chinese Medical Journal (2021) Vol. 134, Iss. 11, pp. 1317-1323
Open Access | Times Cited: 34
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease
Xingjian Zhang, Yan Zhou, Ruixia Ma
Journal of Diabetes and its Complications (2021) Vol. 36, Iss. 1, pp. 108056-108056
Open Access | Times Cited: 19
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus
Richard F. Pollock, Kirsi Norrbacka, Kristina S. Boye, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 393-402
Open Access | Times Cited: 13
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Ara Aboolian, Sofia Urner, Michael Roden, et al.
Handbook of experimental pharmacology (2022), pp. 269-307
Closed Access | Times Cited: 13
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action
Francesco Maranta, Lorenzo Cianfanelli, Manfredi Rizzo, et al.
International Journal of Cardiology (2020) Vol. 329, pp. 205-207
Closed Access | Times Cited: 20
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease
Syed Mohiuddin, Mary E. Ward, William Hollingworth, et al.
PharmacoEconomics - Open (2024) Vol. 8, Iss. 3, pp. 359-371
Open Access | Times Cited: 1
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Oliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 10
A drug utilisation pattern in non-dialysis patients of diabetic nephropathy in a government-run tertiary care hospital in South-Asia
Rajmohan Seetharaman, Manjari Advani, Smita Mali, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2023) Vol. 34, Iss. 3, pp. 371-381
Closed Access | Times Cited: 2
Glucagon-like peptide-1 Receptor Agonists and the Cardiorenal Axis in Type 2 Diabetes: A Focus On Dulaglutide
Richard J. MacIsaac
Future Cardiology (2021) Vol. 17, Iss. 3, pp. 459-473
Open Access | Times Cited: 5
Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
Veronica Sciannameo, Paola Berchialla, Angelo Avogaro, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Are There Different Viewpoints About the Management of Type 2 Diabetes Mellitus and Comorbidities? A Multidisciplinary Spanish Qualitative Research
Xavier Cos, Ricardo Gómez‐Huelgas, Fernando Gómez-Peralta
Diabetes Therapy (2021) Vol. 13, Iss. 1, pp. 189-203
Open Access | Times Cited: 5
Complex metabolic–endocrine syndromes: associations with cardiovascular disease
Andrew J. Krentz
Elsevier eBooks (2023), pp. 39-81
Closed Access | Times Cited: 1
The potential of precision diabetology for type 2 diabetes treatment—evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials
Oliver Kuß, Michael Roden, Sabrina Schlesinger, et al.
Acta Diabetologica (2024)
Open Access
Evaluation of efficacy and safety of combined rosuvastatin and atorvastatin in treating with coronary heart disease
Ke Li, Mengmeng Liu, Xin Yang, et al.
Medicine (2021) Vol. 100, Iss. 24, pp. e26340-e26340
Open Access | Times Cited: 3
Welcome to the Cardiovascular Outcomes Trials Issue
Craig I Coleman, Olivia S. Costa
Future Cardiology (2021) Vol. 17, Iss. 3, pp. 399-402
Closed Access | Times Cited: 1
Phase 3
Zhaoling Meng
(2022), pp. 169-198
Closed Access
Page 1

Scroll to top